University of Oxford
178 articles with University of Oxford
Research published in Lancet Oncology August 24th analyzed that risk by tumor subtype and patient demographics, looking at 1,044 patients from 60 medical centers throughout the UK.
ViewRay, GenesisCare and the University of Oxford Announce Groundbreaking Compassionate Access Programme Now Open to UK Patients with Localized Pancreatic Cancer
ViewRay, the GenesisCare Foundation and the Pancreatic Cancer Research Fund Work Together to Provide MRIdian Radiation Therapy at No Cost to NHS Pancreatic Cancer Patients
Catalent Signs Agreement with AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine AZD1222
Catalent, Inc. announced that Catalent Cell & Gene Therapy will provide drug substance manufacturing to AstraZeneca for the University of Oxford’s adenovirus vector-based COVID-19 vaccine, AZD1222, at Catalent’s commercial gene therapy manufacturing facility located in Harmans, Maryland.
7/27/2020It was a busy week for clinical trial news, with some very important early-stage trial data for various COVID-19 vaccines. Here’s a look.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 3, 2020.
New Capture the Fracture® Partnership Aims for 25% Reduction in the Incidence of Hip and Vertebral Fractures Due to Osteoporosis by 2025
International Osteoporosis Foundation Announces First-of-its-kind Partnership With University of Oxford, Amgen and UCB to Combat Global Public Health Burden of Osteoporosis
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 22, 2020.
The U.S. Biomedical Advanced Research and Development Authority (BARDA) paid more than $1 billion to support the development, production and delivery of the vaccine beginning this fall.
Vaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large-scale distribution of the COVID-19 vaccine candidate
Vaccitech Ltd and the University of Oxford announce an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the University.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 30, 2020.
AstraZeneca and the University of Oxford have partnered on the global development and distribution of Oxford’s COVID-19 vaccine it is developing.
4/27/2020Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.
With a shared commitment to innovation, the alliance aims to support a healthier humanity--starting with healthier guests
Scientists at the University of Eastern Finland and the University of Oxford have shown that small RNA molecules occurring naturally in cells, i.e. microRNAs, are also abundant in cell nuclei.
Blue Water Vaccines, Developing Universal Flu Vaccine, Completes $7m Financing Following Successful Preclinical Study
Blue Water Vaccines, a company developing a universal flu vaccine based on technology developed at the University of Oxford, has closed a $7 million seed capital round led by CincyTech.
Scholars at the University of Oxford have announced their new project, “Citizenship in a Networked Age.” Funded by Templeton World Charity Foundation, the project will culminate in 2020 in a detailed report of the team’s findings and recommendations, which will explore how humans can uphold ideals of citizenship in an evolving technological landscape.
The University of Oxford and Harrington Discovery Institute at University Hospitals Announce New Affiliation to Advance Therapies for Rare Diseases
Joint program combines capabilities to improve treatment options globally for patients with rare diseases
1/4/2019There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
New collaboration with Coalition for Epidemic Preparedness Innovations (CEPI) and The Jenner Institute is latest example of Johnson & Johnson’s ongoing commitment to global pandemic preparedness efforts